Endocannabinoid system in neurodegenerative disorders
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Most neurodegenerative disorders (NDD s) are characterized by cognitive impairment and other neurological defects. The definite cause of and pathways underlying the progression of these NDD s are not well‐defined. Several mechanisms have been proposed to contribute to the development of NDD s. These mechanisms may proceed concurrently or successively, and they differ among cell types at different developmental stages in distinct brain regions. The endocannabinoid system, which involves cannabinoid receptors type 1 (CB 1R) and type 2 (CB 2R), endogenous cannabinoids and the enzymes that catabolize these compounds, has been shown to contribute to the development of NDD s in several animal models and human studies. In this review, we discuss the functions of the endocannabinoid system in NDD s and converse the therapeutic efficacy of targeting the endocannabinoid system to rescue NDD s. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Missense mutations in the asynuclein (a-syn) gene have been shown to cause autosomal dominant familial PD (Polymeropoulos et al. 1997; Kruger et al. 1998; Zarranz et al. 2004), and it has been suggested that a-syn causes the microglia-mediated inflammatory response in PD (Zhang et al. 2005; Austin…”
BackgroundEpidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110 · cited 1×
“The irreversible loss of the DA-mediated control of striatal function leads to bradykinesia, tremor, and rigidity in PD (de Lau and Breteler 2006; Branchi et al. 2008, 2010; Bartels and Leenders 2009).”
BackgroundAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Microglial M1/M2 polarization and metabolic states
Orihuela, R., McPherson, C. A., & Harry, G. J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13139 · Cited by 2,070 · cited 1×
“CB2R activation has been reported to transform microglial cells from the M1 to the M2 phenotype (Orihuela et al. 2016) and to favor phagocytosis (Mecha et al. 2015).”
BackgroundEndogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 4×
“Activation of CB1Rs or inhibition of endocannabinoid-degrading enzymes [FAAH, MAGL, and alpha/beta-Hydrolase domain containing 6 (ABHD6)] was shown to enhance Ab clearance across the blood-brain barrier through increased expression of the low-density lipoprotein receptor-related protein 1 (LRP1) (Shibata et al. 2000).”
BackgroundInfluential
Cited by
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
The Notch pathway in CNS homeostasis and neurodegeneration
Ho, D. M., Artavanis‐Tsakonas, S., & Louvi, A. (2020) · WIREs Developmental Biology · doi:10.1002/wdev.358 · Cited by 90
Syal, C., Kosaraju, J., Hamilton, L., Aumont, A., Chu, A., Sarma, S. N., Thomas, J., Seegobin, M., Dilworth, F. J., He, L., et al. (2020) · Theranostics · doi:10.7150/thno.44962 · Cited by 42
Emerging Therapeutic Role of PPAR–α in Cognition and Emotions
Nisbett, K. E., & Pinna, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00998 · Cited by 37
“Neurosteroids and the endocannabinoid system are increasing in relevance as themes in the studies of many disorders and diseases (Berardi et al., 2016; Basavarajappa et al., 2017; Rasmusson et al., 2017).”
BackgroundDistinct functions of endogenous cannabinoid system in alcohol abuse disorders
Basavarajappa, B. S., Joshi, V., Shivakumar, M., & Subbanna, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14780 · Cited by 37
Self-citationSynaptic Organizers in Alzheimer’s Disease: A Classification Based on Amyloid-β Sensitivity
Lee, A. K., Khaled, H., Chofflet, N., & Takahashi, H. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00281 · Cited by 14
“Indeed, it has been reported that CB1R activity is enhanced in the anterior thalamus in an AD mouse model named 3XTg-AD (Manuel et al., 2016; Basavarajappa et al., 2017).”
BackgroundCannabis, Cannabinoids, and Stroke: Increased Risk or Potential for Protection—A Narrative Review
Carter, C., Laviolette, L., Bietar, B., Zhou, J., & Lehmann, C. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040196 · Cited by 13
“Phytocannabinoids, including THC and CBD, also elicit their effects by binding to the cell membrane receptors of CB1 or CB2 [12].”
Background
Metadata
- Authors
- Basavarajappa, B. S., Shivakumar, M., Joshi, V., & Subbanna, S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2017-07-05
- Volume
- 142
- Issue
- 5
- Pages
- 624-648
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2625733228
- Cited by
- 212
- References
- 33
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.